More than Cholesterol Transporters: Lipoprotein Receptors in CNS Function and Neurodegeneration

Neuron

Volumn 83, Issue 4, 2014, Pages 771-787

  Lane Donovan, Courtney ^a   Philips, Gary T ^a,b   Herz, Joachim ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOER2 PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BETA SECRETASE 1; BRAIN PROTEIN; EPHRIN B2; GLYCOGEN SYNTHASE KINASE 3BETA; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP4 PROTEIN; MEGALIN; MUSK PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; PROTEIN KINASE FYN; REELIN; TAU PROTEIN; UNCLASSIFIED DRUG; VLDLR PROTEIN; AMYLOID; APOLIPOPROTEIN E; CHOLESTEROL; CHYLOMICRON; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; CELL MIGRATION; CENTRAL NERVOUS SYSTEM FUNCTION; CHOLESTEROL METABOLISM; DIAGNOSTIC IMAGING; ENDOCYTOSIS; ENDOSOME; LONG TERM POTENTIATION; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROIMAGING; NEUROMUSCULAR SYNAPSE; PERIPHERAL NERVOUS SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE; VASCULAR AMYLOIDOSIS; CHOLESTEROL TRANSPORT; DISEASE COURSE; GENE FUNCTION; GENETIC VARIABILITY; HUMAN; LIPID METABOLISM; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; ANIMAL; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; CENTRAL NERVOUS SYSTEM; ENDOCYTOSIS; ENDOSOMES; HUMANS; MODELS, NEUROLOGICAL; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; PERIPHERAL NERVOUS SYSTEM; RECEPTORS, LDL; SYNAPTIC TRANSMISSION;

EID: 84907364703     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.08.005     Document Type: Review

References (244)

1. Abramov E., Dolev I., Fogel H., Ciccotosto G.D., Ruff E., Slutsky I. Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat. Neurosci. 2009, 12:1567-1576.
2. Acosta-Baena N., Sepulveda-Falla D., Lopera-Gómez C.M., Jaramillo-Elorza M.C., Moreno S., Aguirre-Acevedo D.C., Saldarriaga A., Lopera F. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol. 2011, 10:213-220.
3. Akaaboune M., Allinquant B., Farza H., Roy K., Magoul R., Fiszman M., Festoff B.W., Hantaï D. Developmental regulation of amyloid precursor protein at the neuromuscular junction in mouse skeletal muscle. Mol. Cell. Neurosci. 2000, 15:355-367.
4. Andersen O.M., Yeung C.H., Vorum H., Wellner M., Andreassen T.K., Erdmann B., Mueller E.C., Herz J., Otto A., Cooper T.G., Willnow T.E. Essential role of the apolipoprotein E receptor-2 in sperm development. J.Biol. Chem. 2003, 278:23989-23995.
5. Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R., Behlke J., von Arnim C.A., Breiderhoff T., Jansen P., Wu X., et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 2005, 102:13461-13466.
6. Aoki M., Volkmann I., Tjernberg L.O., Winblad B., Bogdanovic N. Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain. Neuroreport 2008, 19:1085-1089.
7. Arango-Lasprilla J.C., Cuetos F., Valencia C., Uribe C., Lopera F. Cognitive changes in the preclinical phase of familial Alzheimer's disease. J.Clin. Exp. Neuropsychol. 2007, 29:892-900.
8. Bakker A., Krauss G.L., Albert M.S., Speck C.L., Jones L.R., Stark C.E., Yassa M.A., Bassett S.S., Shelton A.L., Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012, 74:467-474.
9. Bal M., Leitz J., Reese A.L., Ramirez D.M., Durakoglugil M., Herz J., Monteggia L.M., Kavalali E.T. Reelin mobilizes a VAMP7-dependent synaptic vesicle pool and selectively augments spontaneous neurotransmission. Neuron 2013, 80:934-946.
10. Beaven S.W., Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 2006, 57:313-329.
11. Beffert U., Arguin C., Poirier J. The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer's disease. Neurosci. Lett. 1999, 259:29-32.
12. Beffert U., Morfini G., Bock H.H., Reyna H., Brady S.T., Herz J. Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3beta. J.Biol. Chem. 2002, 277:49958-49964.
13. Beffert U., Stolt P.C., Herz J. Functions of lipoprotein receptors in neurons. J.Lipid Res. 2004, 45:403-409.
14. Beffert U., Weeber E.J., Durudas A., Qiu S., Masiulis I., Sweatt J.D., Li W.P., Adelmann G., Frotscher M., Hammer R.E., Herz J. Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron 2005, 47:567-579.
15. Beisiegel U., Weber W., Ihrke G., Herz J., Stanley K.K. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989, 341:162-164.
16. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J.Cereb. Blood Flow Metab. 2007, 27:909-918.
17. Bell R.D., Deane R., Chow N., Long X., Sagare A., Singh I., Streb J.W., Guo H., Rubio A., Van Nostrand W., et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat. Cell Biol. 2009, 11:143-153.
18. Benhayon D., Magdaleno S., Curran T. Binding of purified Reelin to ApoER2 and VLDLR mediates tyrosine phosphorylation of Disabled-1. Brain Res. Mol. Brain Res. 2003, 112:33-45.
19. Björkhem I., Lütjohann D., Diczfalusy U., Ståhle L., Ahlborg G., Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J.Lipid Res. 1998, 39:1594-1600.
20. Bootsma H.P., Ricker L., Diepman L., Gehring J., Hulsman J., Lambrechts D., Leenen L., Majoie M., Schellekens A., de Krom M., Aldenkamp A.P. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 2007, 10:296-303.
21. Botella-López A., Burgaya F., Gavín R., García-Ayllón M.S., Gómez-Tortosa E., Peña-Casanova J., Ureña J.M., Del Río J.A., Blesa R., Soriano E., Sáez-Valero J. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2006, 103:5573-5578.
22. Botella-López A., Cuchillo-Ibáñez I., Cotrufo T., Mok S.S., Li Q.X., Barquero M.S., Dierssen M., Soriano E., Sáez-Valero J. Beta-amyloid controls altered Reelin expression and processing in Alzheimer's disease. Neurobiol. Dis. 2010, 37:682-691.
23. Bouché E., Romero-Ortega M.I., Henkemeyer M., Catchpole T., Leemhuis J., Frotscher M., May P., Herz J., Bock H.H. Reelin induces EphB activation. Cell Res. 2013, 23:473-490.
24. Boyles J.K., Pitas R.E., Wilson E., Mahley R.W., Taylor J.M. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J.Clin. Invest. 1985, 76:1501-1513.
25. Brecht W.J., Harris F.M., Chang S., Tesseur I., Yu G.Q., Xu Q., Dee Fish J., Wyss-Coray T., Buttini M., Mucke L., et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J.Neurosci. 2004, 24:2527-2534.
26. Brich J., Shie F.S., Howell B.W., Li R., Tus K., Wakeland E.K., Jin L.W., Mumby M., Churchill G., Herz J., Cooper J.A. Genetic modulation of tau phosphorylation in the mouse. J.Neurosci. 2003, 23:187-192.
27. Brodeur J., Thériault C., Lessard-Beaudoin M., Marcil A., Dahan S., Lavoie C. LDLR-related protein 10 (LRP10) regulates amyloid precursor protein (APP) trafficking and processing: evidence for a role in Alzheimer's disease. Mol. Neurodegener. 2012, 7:31.
28. Cai H., Wang Y., McCarthy D., Wen H., Borchelt D.R., Price D.L., Wong P.C. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 2001, 4:233-234.
29. Cam J.A., Zerbinatti C.V., Knisely J.M., Hecimovic S., Li Y., Bu G. The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J.Biol. Chem. 2004, 279:29639-29646.
30. Cam J.A., Zerbinatti C.V., Li Y., Bu G. Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the beta-amyloid precursor protein. J.Biol. Chem. 2005, 280:15464-15470.
31. Cao X., Südhof T.C. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001, 293:115-120.
32. Carlo A.S., Gustafsen C., Mastrobuoni G., Nielsen M.S., Burgert T., Hartl D., Rohe M., Nykjaer A., Herz J., Heeren J., et al. The pro-neurotrophin receptor sortilin is a major neuronal apolipoprotein E receptor for catabolism of amyloid-β peptide in the brain. J.Neurosci. 2013, 33:358-370.
33. Carstea E.D., Morris J.A., Coleman K.G., Loftus S.K., Zhang D., Cummings C., Gu J., Rosenfeld M.A., Pavan W.J., Krizman D.B., et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 1997, 277:228-231.
34. Caselli R.J., Dueck A.C., Osborne D., Sabbagh M.N., Connor D.J., Ahern G.L., Baxter L.C., Rapcsak S.Z., Shi J., Woodruff B.K., et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N.Engl. J. Med. 2009, 361:255-263.
35. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., Fagan A.M., Morris J.C., Mawuenyega K.G., Cruchaga C., et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 2011, 3:89ra57.
36. Castellano J.M., Deane R., Gottesdiener A.J., Verghese P.B., Stewart F.R., West T., Paoletti A.C., Kasper T.R., DeMattos R.B., Zlokovic B.V., Holtzman D.M. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc. Natl. Acad. Sci. USA 2012, 109:15502-15507.
37. Cataldo A.M., Barnett J.L., Pieroni C., Nixon R.A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J.Neurosci. 1997, 17:6142-6151.
38. Cataldo A.M., Peterhoff C.M., Troncoso J.C., Gomez-Isla T., Hyman B.T., Nixon R.A. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 2000, 157:277-286.
39. Chen Y., Beffert U., Ertunc M., Tang T.S., Kavalali E.T., Bezprozvanny I., Herz J. Reelin modulates NMDA receptor activity in cortical neurons. J.Neurosci. 2005, 25:8209-8216.
40. Chen Y., Durakoglugil M.S., Xian X., Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc. Natl. Acad. Sci. USA 2010, 107:12011-12016.
41. Chen K., Ayutyanont N., Langbaum J.B., Fleisher A.S., Reschke C., Lee W., Liu X., Alexander G.E., Bandy D., Caselli R.J., Reiman E.M. Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares. Neuroimage 2012, 60:2316-2322.
42. Cheng H., Xu J., McKeel D.W., Han X. Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study. Cell. Mol. Biol. (Noisy-le-grand) 2003, 49:809-818.
43. Chin J., Palop J.J., Puoliväli J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J.Neurosci. 2005, 25:9694-9703.
44. Chin J., Massaro C.M., Palop J.J., Thwin M.T., Yu G.Q., Bien-Ly N., Bender A., Mucke L. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J.Neurosci. 2007, 27:2727-2733.
45. Choi H.Y., Liu Y., Tennert C., Sugiura Y., Karakatsani A., Kröger S., Johnson E.B., Hammer R.E., Lin W., Herz J. APP interacts with LRP4 and agrin to coordinate the development of the neuromuscular junction in mice. Elife (Cambridge) 2013, 2:e00220.
46. Chow V.W., Mattson M.P., Wong P.C., Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med. 2010, 12:1-12.
47. Christ A., Christa A., Kur E., Lioubinski O., Bachmann S., Willnow T.E., Hammes A. LRP2 is an auxiliary SHH receptor required to condition the forebrain ventral midline for inductive signals. Dev. Cell 2012, 22:268-278.
48. Christie R.H., Chung H., Rebeck G.W., Strickland D., Hyman B.T. Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system and in Alzheimer's disease. J.Neuropathol. Exp. Neurol. 1996, 55:491-498.
49. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels invivo. Neuron 2005, 48:913-922.
50. Cirrito J.R., Kang J.E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Bu G., Mennerick S., Holtzman D.M. Endocytosis is required for synaptic activity-dependent release of amyloid-beta invivo. Neuron 2008, 58:42-51.
51. Clatworthy A.E., Stockinger W., Christie R.H., Schneider W.J., Nimpf J., Hyman B.T., Rebeck G.W. Expression and alternate splicing of apolipoprotein E receptor 2 in brain. Neuroscience 1999, 90:903-911.
52. Clifford P.M., Zarrabi S., Siu G., Kinsler K.J., Kosciuk M.C., Venkataraman V., D'Andrea M.R., Dinsmore S., Nagele R.G. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res. 2007, 1142:223-236.
53. Cole S.L., Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol. Neurodegener. 2007, 2:22.
54. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
55. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994, 7:180-184.
56. Cuetos F., Arango-Lasprilla J.C., Uribe C., Valencia C., Lopera F. Linguistic changes in verbal expression: a preclinical marker of Alzheimer's disease. J.Int. Neuropsychol. Soc. 2007, 13:433-439.
57. Curran T., D'Arcangelo G. Role of reelin in the control of brain development. Brain Res. Brain Res. Rev. 1998, 26:285-294.
58. D'Amelio M., Cavallucci V., Middei S., Marchetti C., Pacioni S., Ferri A., Diamantini A., De Zio D., Carrara P., Battistini L., et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat. Neurosci. 2011, 14:69-76.
59. D'Arcangelo G., Miao G.G., Chen S.C., Soares H.D., Morgan J.I., Curran T. A protein related to extracellular matrix proteins deleted in the mouse mutant reeler. Nature 1995, 374:719-723.
60. D'Arcangelo G., Homayouni R., Keshvara L., Rice D.S., Sheldon M., Curran T. Reelin is a ligand for lipoprotein receptors. Neuron 1999, 24:471-479.
61. Dalva M.B., Takasu M.A., Lin M.Z., Shamah S.M., Hu L., Gale N.W., Greenberg M.E. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 2000, 103:945-956.
62. Das U., Scott D.A., Ganguly A., Koo E.H., Tang Y., Roy S. Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron 2013, 79:447-460.
63. Davis C.G., Goldstein J.L., Südhof T.C., Anderson R.G., Russell D.W., Brown M.S. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature 1987, 326:760-765.
64. Dean D.C., Jerskey B.A., Chen K., Protas H., Thiyyagura P., Roontiva A., O'Muircheartaigh J., Dirks H., Waskiewicz N., Lehman K., et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol. 2014, 71:11-22.
65. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., Zlokovic B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J.Clin. Invest. 2008, 118:4002-4013.
66. Dodson S.E., Gearing M., Lippa C.F., Montine T.J., Levey A.I., Lah J.J. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J.Neuropathol. Exp. Neurol. 2006, 65:866-872.
67. Dong L.M., Weisgraber K.H. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J.Biol. Chem. 1996, 271:19053-19057.
68. Dong L.M., Wilson C., Wardell M.R., Simmons T., Mahley R.W., Weisgraber K.H., Agard D.A. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J.Biol. Chem. 1994, 269:22358-22365.
69. Duit S., Mayer H., Blake S.M., Schneider W.J., Nimpf J. Differential functions of ApoER2 and very low density lipoprotein receptor in Reelin signaling depend on differential sorting of the receptors. J.Biol. Chem. 2010, 285:4896-4908.
70. Dumanis S.B., Chamberlain K.A., Jin Sohn Y., Jin Lee Y., Guénette S.Y., Suzuki T., Mathews P.M., Pak D.Ts., Rebeck G.W., Suh Y.H., et al. FE65 as a link between VLDLR and APP to regulate their trafficking and processing. Mol. Neurodegener. 2012, 7:9.
71. Durakoglugil M.S., Chen Y., White C.L., Kavalali E.T., Herz J. Reelin signaling antagonizes beta-amyloid at the synapse. Proc. Natl. Acad. Sci. USA 2009, 106:15938-15943.
72. Eckhardt M. The role and metabolism of sulfatide in the nervous system. Mol. Neurobiol. 2008, 37:93-103.
73. Ehehalt R., Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J.Cell Biol. 2003, 160:113-123.
74. Ellis R.J., Olichney J.M., Thal L.J., Mirra S.S., Morris J.C., Beekly D., Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996, 46:1592-1596.
75. Esser V., Limbird L.E., Brown M.S., Goldstein J.L., Russell D.W. Mutational analysis of the ligand binding domain of the low density lipoprotein receptor. J.Biol. Chem. 1988, 263:13282-13290.
76. Falconer D.S. Two new mutants, 'trembler' and 'reeler', with neurological actions in the house mouse (Mus musculus L.). J.Genet. 1951, 50:192-201.
77. Fan Q.W., Iosbe I., Asou H., Yanagisawa K., Michikawa M. Expression and regulation of apolipoprotein E receptors in the cells of the central nervous system in culture: A review. J Am Aging Assoc 2001, 24:1-10.
78. Filippini N., MacIntosh B.J., Hough M.G., Goodwin G.M., Frisoni G.B., Smith S.M., Matthews P.M., Beckmann C.F., Mackay C.E. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc. Natl. Acad. Sci. USA 2009, 106:7209-7214.
79. Fryer J.D., Simmons K., Parsadanian M., Bales K.R., Paul S.M., Sullivan P.M., Holtzman D.M. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J.Neurosci. 2005, 25:2803-2810.
80. Fuentealba R.A., Barría M.I., Lee J., Cam J., Araya C., Escudero C.A., Inestrosa N.C., Bronfman F.C., Bu G., Marzolo M.P. ApoER2 expression increases Abeta production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of gamma-secretase activity. Mol. Neurodegener. 2007, 2:14.
81. Ghosal K., Stathopoulos A., Pimplikar S.W. APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS ONE 2010, 5:e11866.
82. Go G.W., Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J. Biol. Med. 2012, 85:19-28.
83. Gotthardt M., Trommsdorff M., Nevitt M.F., Shelton J., Richardson J.A., Stockinger W., Nimpf J., Herz J. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J.Biol. Chem. 2000, 275:25616-25624.
84. Götz J., Gladbach A., Pennanen L., van Eersel J., Schild A., David D., Ittner L.M. Animal models reveal role for tau phosphorylation in human disease. Biochim. Biophys. Acta 2010, 1802:860-871.
85. Grant S.G., O'Dell T.J., Karl K.A., Stein P.L., Soriano P., Kandel E.R. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science 1992, 258:1903-1910.
86. Greenberg S.M., Rebeck G.W., Vonsattel J.P., Gomez-Isla T., Hyman B.T. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 1995, 38:254-259.
87. Grimmer T., Tholen S., Yousefi B.H., Alexopoulos P., Förschler A., Förstl H., Henriksen G., Klunk W.E., Mathis C.A., Perneczky R., et al. Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease. Biol. Psychiatry 2010, 68:879-884.
88. Gustafsen C., Glerup S., Pallesen L.T., Olsen D., Andersen O.M., Nykjær A., Madsen P., Petersen C.M. Sortilin and SorLA display distinct roles in processing and trafficking of amyloid precursor protein. J.Neurosci. 2013, 33:64-71.
89. Hafezi-Moghadam A., Thomas K.L., Wagner D.D. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am. J. Physiol. Cell Physiol. 2007, 292:C1256-C1262.
90. Han X., M Holtzman D., McKeel D.W., Kelley J., Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J.Neurochem. 2002, 82:809-818.
91. Han X., Fagan A.M., Cheng H., Morris J.C., Xiong C., Holtzman D.M. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann. Neurol. 2003, 54:115-119.
92. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5:405-414.
93. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
94. Harris F.M., Brecht W.J., Xu Q., Tesseur I., Kekonius L., Wyss-Coray T., Fish J.D., Masliah E., Hopkins P.C., Scearce-Levie K., et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. USA 2003, 100:10966-10971.
95. He X., Cooley K., Chung C.H., Dashti N., Tang J. Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production. J.Neurosci. 2007, 27:4052-4060.
96. Heeren J., Grewal T., Laatsch A., Becker N., Rinninger F., Rye K.A., Beisiegel U. Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J.Biol. Chem. 2004, 279:55483-55492.
97. Hellwig S., Hack I., Kowalski J., Brunne B., Jarowyj J., Unger A., Bock H.H., Junghans D., Frotscher M. Role for Reelin in neurotransmitter release. J.Neurosci. 2011, 31:2352-2360.
98. Herring A., Donath A., Steiner K.M., Widera M.P., Hamzehian S., Kanakis D., Kölble K., ElAli A., Hermann D.M., Paulus W., Keyvani K. Reelin depletion is an early phenomenon of Alzheimer's pathology. J.Alzheimers Dis. 2012, 30:963-979.
99. Herz J., Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat. Rev. Neurosci. 2006, 7:850-859.
100. Herz J., Hamann U., Rogne S., Myklebost O., Gausepohl H., Stanley K.K. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 1988, 7:4119-4127.
101. Hiesberger T., Trommsdorff M., Howell B.W., Goffinet A., Mumby M.C., Cooper J.A., Herz J. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron 1999, 24:481-489.
102. Hoe H.S., Wessner D., Beffert U., Becker A.G., Matsuoka Y., Rebeck G.W. F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. Mol. Cell. Biol. 2005, 25:9259-9268.
103. Hoe H.S., Pocivavsek A., Chakraborty G., Fu Z., Vicini S., Ehlers M.D., Rebeck G.W. Apolipoprotein E receptor 2 interactions with the N-methyl-D-aspartate receptor. J.Biol. Chem. 2006, 281:3425-3431.
104. Hong S.E., Shugart Y.Y., Huang D.T., Shahwan S.A., Grant P.E., Hourihane J.O., Martin N.D., Walsh C.A. Autosomal recessive lissencephaly with cerebellar hypoplasia is associated with human RELN mutations. Nat. Genet. 2000, 26:93-96.
105. Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R., Carlson G.A., Lanier L.M., Yuan L.L., et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68:1067-1081.
106. Howell B.W., Gertler F.B., Cooper J.A. Mouse disabled (mDab1): a Src binding protein implicated in neuronal development. EMBO J. 1997, 16:121-132.
107. Huang Y., Liu X.Q., Wyss-Coray T., Brecht W.J., Sanan D.A., Mahley R.W. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl. Acad. Sci. USA 2001, 98:8838-8843.
108. Hughes S.R., Khorkova O., Goyal S., Knaeblein J., Heroux J., Riedel N.G., Sahasrabudhe S. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc. Natl. Acad. Sci. USA 1998, 95:3275-3280.
109. Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S., et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012, 482:216-220.
110. Ittner L.M., Götz J. Amyloid-β and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:65-72.
111. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wölfing H., Chieng B.C., Christie M.J., Napier I.A., et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
112. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
113. Jin C., Liu X., Zhang F., Wu Y., Yuan J., Zhu J., Zhang F., Wang G., Cheng Z. An updated meta-analysis of the association between SORL1 variants and the risk for sporadic Alzheimer's disease. J.Alzheimers Dis. 2013, 37:429-437.
114. Jo J., Whitcomb D.J., Olsen K.M., Kerrigan T.L., Lo S.C., Bru-Mercier G., Dickinson B., Scullion S., Sheng M., Collingridge G., Cho K. Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. Nat. Neurosci. 2011, 14:545-547.
115. Johnson E.B., Steffen D.J., Lynch K.W., Herz J. Defective splicing of Megf7/Lrp4, a regulator of distal limb development, in autosomal recessive mulefoot disease. Genomics 2006, 88:600-609.
116. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 2007, 32:577-595.
117. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron 2003, 37:925-937.
118. Kanekiyo T., Bu G. Receptor-associated protein interacts with amyloid-beta peptide and promotes its cellular uptake. J.Biol. Chem. 2009, 284:33352-33359.
119. Kanekiyo T., Liu C.C., Shinohara M., Li J., Bu G. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β. J.Neurosci. 2012, 32:16458-16465.
120. Kanekiyo T., Cirrito J.R., Liu C.C., Shinohara M., Li J., Schuler D.R., Shinohara M., Holtzman D.M., Bu G. Neuronal clearance of amyloid-β by endocytic receptor LRP1. J.Neurosci. 2013, 33:19276-19283.
121. Kanekiyo T., Xu H., Bu G. ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?. Neuron 2014, 81:740-754.
122. Kantarci S., Al-Gazali L., Hill R.S., Donnai D., Black G.C., Bieth E., Chassaing N., Lacombe D., Devriendt K., Teebi A., et al. Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat. Genet. 2007, 39:957-959.
123. Karner C.M., Dietrich M.F., Johnson E.B., Kappesser N., Tennert C., Percin F., Wollnik B., Carroll T.J., Herz J. Lrp4 regulates initiation of ureteric budding and is crucial for kidney formation-a mouse model for Cenani-Lenz syndrome. PLoS ONE 2010, 5:e10418.
124. Kim N., Burden S.J. MuSK controls where motor axons grow and form synapses. Nat. Neurosci. 2008, 11:19-27.
125. Kim D.H., Iijima H., Goto K., Sakai J., Ishii H., Kim H.J., Suzuki H., Kondo H., Saeki S., Yamamoto T. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J.Biol. Chem. 1996, 271:8373-8380.
126. Kim J., Onstead L., Randle S., Price R., Smithson L., Zwizinski C., Dickson D.W., Golde T., McGowan E. Abeta40 inhibits amyloid deposition invivo. J.Neurosci. 2007, 27:627-633.
127. Kim N., Stiegler A.L., Cameron T.O., Hallock P.T., Gomez A.M., Huang J.H., Hubbard S.R., Dustin M.L., Burden S.J. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008, 135:334-342.
128. Kim Y., Lee Y.I., Seo M., Kim S.Y., Lee J.E., Youn H.D., Kim Y.S., Juhnn Y.S. Calcineurin dephosphorylates glycogen synthase kinase-3 beta at serine-9 in neuroblast-derived cells. J.Neurochem. 2009, 111:344-354.
129. Klein R. Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat. Neurosci. 2009, 12:15-20.
130. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
131. Kounnas M.Z., Argraves W.S., Strickland D.K. The 39-kDa receptor-associated protein interacts with two members of the low density lipoprotein receptor family, alpha 2-macroglobulin receptor and glycoprotein 330. J.Biol. Chem. 1992, 267:21162-21166.
132. Kramer P.L., Xu H., Woltjer R.L., Westaway S.K., Clark D., Erten-Lyons D., Kaye J.A., Welsh-Bohmer K.A., Troncoso J.C., Markesbery W.R., et al. Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol. Aging 2011, 32:2113-2122.
133. Krstic D., Pfister S., Notter T., Knuesel I. Decisive role of Reelin signaling during early stages of Alzheimer's disease. Neuroscience 2013, 246:108-116.
134. Lakshmana M.K., Yoon I.S., Chen E., Bianchi E., Koo E.H., Kang D.E. Novel role of RanBP9 in BACE1 processing of amyloid precursor protein and amyloid beta peptide generation. J.Biol. Chem. 2009, 284:11863-11872.
135. Lakshmana M.K., Chung J.Y., Wickramarachchi S., Tak E., Bianchi E., Koo E.H., Kang D.E. A fragment of the scaffolding protein RanBP9 is increased in Alzheimer's disease brains and strongly potentiates amyloid-beta peptide generation. FASEB J. 2010, 24:119-127.
136. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099. European Alzheimer's Disease Initiative Investigators.
137. Laurén J., Gimbel D.A., Nygaard H.B., Gilbert J.W., Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457:1128-1132.
138. Lawn R.M., Wade D.P., Garvin M.R., Wang X., Schwartz K., Porter J.G., Seilhamer J.J., Vaughan A.M., Oram J.F. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J.Clin. Invest. 1999, 104:R25-R31.
139. Leeb C., Eresheim C., Nimpf J. Clusterin is a ligand for apolipoprotein E receptor 2 (ApoER2) and very low density lipoprotein receptor (VLDLR) and signals via the Reelin-signaling pathway. J.Biol. Chem. 2014, 289:4161-4172.
140. Li Y., Lu W., Marzolo M.P., Bu G. Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates. J.Biol. Chem. 2001, 276:18000-18006.
141. Li Y., Pawlik B., Elcioglu N., Aglan M., Kayserili H., Yigit G., Percin F., Goodman F., Nürnberg G., Cenani A., et al. LRP4 mutations alter Wnt/beta-catenin signaling and cause limb and kidney malformations in Cenani-Lenz syndrome. Am. J. Hum. Genet. 2010, 86:696-706.
142. Li S., Jin M., Koeglsperger T., Shepardson N.E., Shankar G.M., Selkoe D.J. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J.Neurosci. 2011, 31:6627-6638.
143. Li X., Kumar Y., Zempel H., Mandelkow E.M., Biernat J., Mandelkow E. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J. 2011, 30:4825-4837.
144. Li J., Kanekiyo T., Shinohara M., Zhang Y., LaDu M.J., Xu H., Bu G. Differential regulation of amyloid-β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J.Biol. Chem. 2012, 287:44593-44601.
145. Liu C.X., Musco S., Lisitsina N.M., Forgacs E., Minna J.D., Lisitsyn N.A. LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res. 2000, 60:1961-1967.
146. Liu Q., Trotter J., Zhang J., Peters M.M., Cheng H., Bao J., Han X., Weeber E.J., Bu G. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J.Neurosci. 2010, 30:17068-17078.
147. Lopera F., Ardilla A., Martínez A., Madrigal L., Arango-Viana J.C., Lemere C.A., Arango-Lasprilla J.C., Hincapíe L., Arcos-Burgos M., Ossa J.E., et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997, 277:793-799.
148. Mahley R.W., Huang Y. Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 2012, 76:871-885.
149. Mauch D.H., Nägler K., Schumacher S., Göritz C., Müller E.C., Otto A., Pfrieger F.W. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001, 294:1354-1357.
150. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774.
151. May P.C., Lampert-Etchells M., Johnson S.A., Poirier J., Masters J.N., Finch C.E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990, 5:831-839.
152. May P., Rohlmann A., Bock H.H., Zurhove K., Marth J.D., Schomburg E.D., Noebels J.L., Beffert U., Sweatt J.D., Weeber E.J., Herz J. Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol. Cell. Biol. 2004, 24:8872-8883.
153. McGowan E., Pickford F., Kim J., Onstead L., Eriksen J., Yu C., Skipper L., Murphy M.P., Beard J., Das P., et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005, 47:191-199.
154. Moestrup S.K., Verroust P.J. Megalin- and cubilin-mediated endocytosis of protein-bound vitamins, lipids, and hormones in polarized epithelia. Annu. Rev. Nutr. 2001, 21:407-428.
155. Morley J.E., Farr S.A., Banks W.A., Johnson S.N., Yamada K.A., Xu L. A physiological role for amyloid-beta protein:enhancement of learning and memory. J.Alzheimers Dis. 2010, 19:441-449.
156. Morris J.C., Roe C.M., Grant E.A., Head D., Storandt M., Goate A.M., Fagan A.M., Holtzman D.M., Mintun M.A. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 2009, 66:1469-1475.
157. Morrow J.A., Hatters D.M., Lu B., Hochtl P., Oberg K.A., Rupp B., Weisgraber K.H. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J.Biol. Chem. 2002, 277:50380-50385.
158. Mulot S.F., Hughes K., Woodgett J.R., Anderton B.H., Hanger D.P. PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be mimicked by invitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta. FEBS Lett. 1994, 349:359-364.
159. Muratoglu S.C., Belgrave S., Lillis A.P., Migliorini M., Robinson S., Smith E., Zhang L., Strickland D.K. Macrophage LRP1 suppresses neo-intima formation during vascular remodeling by modulating the TGF-β signaling pathway. PLoS ONE 2011, 6:e28846.
160. Nakayama M., Nakajima D., Nagase T., Nomura N., Seki N., Ohara O. Identification of high-molecular-weight proteins with multiple EGF-like motifs by motif-trap screening. Genomics 1998, 51:27-34.
161. Narita M., Holtzman D.M., Schwartz A.L., Bu G. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J.Neurochem. 1997, 69:1904-1911.
162. Naureckiene S., Sleat D.E., Lackland H., Fensom A., Vanier M.T., Wattiaux R., Jadot M., Lobel P. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000, 290:2298-2301.
163. Nicoll J.A., Burnett C., Love S., Graham D.I., Ironside J.W., Vinters H.V. High frequency of apolipoprotein E epsilon 2 in patients with cerebral hemorrhage due to cerebral amyloid angiopathy. Ann. Neurol. 1996, 39:682-683.
164. Nikolaev A., McLaughlin T., O'Leary D.D., Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
165. Nishitsuji K., Hosono T., Nakamura T., Bu G., Michikawa M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an invitro blood-brain barrier model. J.Biol. Chem. 2011, 286:17536-17542.
166. Niu S., Yabut O., D'Arcangelo G. The Reelin signaling pathway promotes dendritic spine development in hippocampal neurons. J.Neurosci. 2008, 28:10339-10348.
167. Nolt M.J., Lin Y., Hruska M., Murphy J., Sheffler-Colins S.I., Kayser M.S., Passer J., Bennett M.V., Zukin R.S., Dalva M.B. EphB controls NMDA receptor function and synaptic targeting in a subunit-specific manner. J.Neurosci. 2011, 31:5353-5364.
168. Nomura I., Takechi H., Kato N. Intraneuronally injected amyloid β inhibits long-term potentiation in rat hippocampal slices. J.Neurophysiol. 2012, 107:2526-2531.
169. Novak S., Hiesberger T., Schneider W.J., Nimpf J. A new low density lipoprotein receptor homologue with 8 ligand binding repeats in brain of chicken and mouse. J.Biol. Chem. 1996, 271:11732-11736.
170. Ozcelik T., Akarsu N., Uz E., Caglayan S., Gulsuner S., Onat O.E., Tan M., Tan U. Mutations in the very low-density lipoprotein receptor VLDLR cause cerebellar hypoplasia and quadrupedal locomotion in humans. Proc. Natl. Acad. Sci. USA 2008, 105:4232-4236.
171. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
172. Parsons M.P., Raymond L.A. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 2014, 82:279-293.
173. Perrin R.J., Fagan A.M., Holtzman D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009, 461:916-922.
174. Pitas R.E., Boyles J.K., Lee S.H., Foss D., Mahley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 1987, 917:148-161.
175. Protas H.D., Chen K., Langbaum J.B., Fleisher A.S., Alexander G.E., Lee W., Bandy D., de Leon M.J., Mosconi L., Buckley S., et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol. 2013, 70:320-325.
176. Puzzo D., Privitera L., Leznik E., Fà M., Staniszewski A., Palmeri A., Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J.Neurosci. 2008, 28:14537-14545.
177. Puzzo D., Privitera L., Fa' M., Staniszewski A., Hashimoto G., Aziz F., Sakurai M., Ribe E.M., Troy C.M., Mercken M., et al. Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol. 2011, 69:819-830.
178. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J.Biol. Chem. 1998, 273:32730-32738.
179. Quiroz Y.T., Budson A.E., Celone K., Ruiz A., Newmark R., Castrillón G., Lopera F., Stern C.E. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann. Neurol. 2010, 68:865-875.
180. Ranganathan S., Noyes N.C., Migliorini M., Winkles J.A., Battey F.D., Hyman B.T., Smith E., Yepes M., Mikhailenko I., Strickland D.K. LRAD3, a novel low-density lipoprotein receptor family member that modulates amyloid precursor protein trafficking. J.Neurosci. 2011, 31:10836-10846.
181. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2009, 106:6820-6825.
182. Rellin L., Heeren J., Beisiegel U. Recycling of apolipoprotein E is not associated with cholesterol efflux in neuronal cells. Biochim. Biophys. Acta 2008, 1781:232-238.
183. Renner M., Lacor P.N., Velasco P.T., Xu J., Contractor A., Klein W.L., Triller A. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010, 66:739-754.
184. Rensen P.C., Jong M.C., van Vark L.C., van der Boom H., Hendriks W.L., van Berkel T.J., Biessen E.A., Havekes L.M. Apolipoprotein E is resistant to intracellular degradation invitro and invivo. Evidence for retroendocytosis. J.Biol. Chem. 2000, 275:8564-8571.
185. Rensink A.A., de Waal R.M., Kremer B., Verbeek M.M. Pathogenesis of cerebral amyloid angiopathy. Brain Res. Brain Res. Rev. 2003, 43:207-223.
186. Rhinn H., Fujita R., Qiang L., Cheng R., Lee J.H., Abeliovich A. Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease. Nature 2013, 500:45-50.
187. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
188. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007, 39:168-177.
189. Rogers J.T., Rusiana I., Trotter J., Zhao L., Donaldson E., Pak D.T., Babus L.W., Peters M., Banko J.L., Chavis P., et al. Reelin supplementation enhances cognitive ability, synaptic plasticity, and dendritic spine density. Learn. Mem. 2011, 18:558-564.
190. Rogers J.T., Zhao L., Trotter J.H., Rusiana I., Peters M.M., Li Q., Donaldson E., Banko J.L., Keenoy K.E., Rebeck G.W., et al. Reelin supplementation recovers sensorimotor gating, synaptic plasticity and associative learning deficits in the heterozygous reeler mouse. J.Psychopharmacol. (Oxford) 2013, 27:386-395.
191. Rohlmann A., Gotthardt M., Hammer R.E., Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J.Clin. Invest. 1998, 101:689-695.
192. Saito A., Pietromonaco S., Loo A.K., Farquhar M.G. Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family. Proc. Natl. Acad. Sci. USA 1994, 91:9725-9729.
193. Sanchez P.E., Zhu L., Verret L., Vossel K.A., Orr A.G., Cirrito J.R., Devidze N., Ho K., Yu G.Q., Palop J.J., Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc. Natl. Acad. Sci. USA 2012, 109:E2895-E2903.
194. Scherzer C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I., Lah J.J. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch. Neurol. 2004, 61:1200-1205.
195. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90:9649-9653.
196. Schmidt V., Sporbert A., Rohe M., Reimer T., Rehm A., Andersen O.M., Willnow T.E. SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J.Biol. Chem. 2007, 282:32956-32964.
197. Schmidt V., Baum K., Lao A., Rateitschak K., Schmitz Y., Teichmann A., Wiesner B., Petersen C.M., Nykjaer A., Wolf J., et al. Quantitative modelling of amyloidogenic processing and its influence by SORLA in Alzheimer's disease. EMBO J. 2012, 31:187-200.
198. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
199. Sheline Y.I., Morris J.C., Snyder A.Z., Price J.L., Yan Z., D'Angelo G., Liu C., Dixit S., Benzinger T., Fagan A., et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J.Neurosci. 2010, 30:17035-17040.
200. Sheng M., Sabatini B.L., Südhof T.C. Synapses and Alzheimer's disease. Cold Spring Harb. Perspect. Biol. 2012, 4:4.
201. Shipton O.A., Leitz J.R., Dworzak J., Acton C.E., Tunbridge E.M., Denk F., Dawson H.N., Vitek M.P., Wade-Martins R., Paulsen O., Vargas-Caballero M. Tau protein is required for amyloid beta-induced impairment of hippocampal long-term potentiation. J.Neurosci. 2011, 31:1688-1692.
202. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 2005, 8:1051-1058.
203. Soba P., Eggert S., Wagner K., Zentgraf H., Siehl K., Kreger S., Löwer A., Langer A., Merdes G., Paro R., et al. Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J. 2005, 24:3624-3634.
204. Soulé J., Penke Z., Kanhema T., Alme M.N., Laroche S., Bramham C.R. Object-place recognition learning triggers rapid induction of plasticity-related immediate early genes and synaptic proteins in the rat dentate gyrus. Neural Plast. 2008, 2008:269097.
205. Spoelgen R., Hammes A., Anzenberger U., Zechner D., Andersen O.M., Jerchow B., Willnow T.E. LRP2/megalin is required for patterning of the ventral telencephalon. Development 2005, 132:405-414.
206. St George-Hyslop P., Fraser P.E. Assembly of the presenilin γ-/ε-secretase complex. J.Neurochem. 2012, 120(Suppl 1):84-88.
207. Strasser V., Fasching D., Hauser C., Mayer H., Bock H.H., Hiesberger T., Herz J., Weeber E.J., Sweatt J.D., Pramatarova A., et al. Receptor clustering is involved in Reelin signaling. Mol. Cell. Biol. 2004, 24:1378-1386.
208. Strickland D.K., Ashcom J.D., Williams S., Burgess W.H., Migliorini M., Argraves W.S. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J.Biol. Chem. 1990, 265:17401-17404.
209. Tackenberg C., Grinschgl S., Trutzel A., Santuccione A.C., Frey M.C., Konietzko U., Grimm J., Brandt R., Nitsch R.M. NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis. 2013, 4:e608.
210. Takahashi S., Kawarabayasi Y., Nakai T., Sakai J., Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl. Acad. Sci. USA 1992, 89:9252-9256.
211. Talantova M., Sanz-Blasco S., Zhang X., Xia P., Akhtar M.W., Okamoto S.I., Dziewczapolski G., Nakamura T., Cao G., Pratt A.E., et al. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. USA 2013, 110:E2518-E2527.
212. Tamai K., Semenov M., Kato Y., Spokony R., Liu C., Katsuyama Y., Hess F., Saint-Jeannet J.P., He X. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000, 407:530-535.
213. Tampellini D., Rahman N., Gallo E.F., Huang Z., Dumont M., Capetillo-Zarate E., Ma T., Zheng R., Lu B., Nanus D.M., et al. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J.Neurosci. 2009, 29:9704-9713.
214. Taylor C.J., Ireland D.R., Ballagh I., Bourne K., Marechal N.M., Turner P.R., Bilkey D.K., Tate W.P., Abraham W.C. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol. Dis. 2008, 31:250-260.
215. Tirado V., Motta M., Aguirre-Acevedo D.C., Pineda D.A., Lopera F. [Analysis of intrusive errors in a memory test as possible pre-clinical marker of familial Alzheimer disease, in E280A presenilin-1 mutation carrier]. Rev. Neurol. 2008, 47:290-294.
216. Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., Zlokovic B., Smith J.D., Ladu M.J., Rostagno A., et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem. J. 2000, 348:359-365.
217. Trommsdorff M., Gotthardt M., Hiesberger T., Shelton J., Stockinger W., Nimpf J., Hammer R.E., Richardson J.A., Herz J. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 1999, 97:689-701.
218. Van Vickle G.D., Esh C.L., Kokjohn T.A., Patton R.L., Kalback W.M., Luehrs D.C., Beach T.G., Newel A.J., Lopera F., Ghetti B., et al. Presenilin-1 280Glu->Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer's disease. Mol. Med. 2008, 14:184-194.
219. Verghese P.B., Castellano J.M., Garai K., Wang Y., Jiang H., Shah A., Bu G., Frieden C., Holtzman D.M. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc. Natl. Acad. Sci. USA 2013, 110:E1807-E1816.
220. Vingtdeux V., Marambaud P. Identification and biology of α-secretase. J.Neurochem. 2012, 120(Suppl 1):34-45.
221. Vinters H.V. Cerebral amyloid angiopathy. A critical review. Stroke 1987, 18:311-324.
222. Wahrle S.E., Jiang H., Parsadanian M., Hartman R.E., Bales K.R., Paul S.M., Holtzman D.M. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J.Biol. Chem. 2005, 280:43236-43242.
223. Wahrle S.E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C.L., Bales K.R., et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J.Clin. Invest. 2008, 118:671-682.
224. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation invivo. Nature 2002, 416:535-539.
225. Wang P., Yang G., Mosier D.R., Chang P., Zaidi T., Gong Y.D., Zhao N.M., Dominguez B., Lee K.F., Gan W.B., Zheng H. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J.Neurosci. 2005, 25:1219-1225.
226. Wang B., Yang L., Wang Z., Zheng H. Amyolid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter. Proc. Natl. Acad. Sci. USA 2007, 104:14140-14145.
227. Wang X., Wang Z., Chen Y., Huang X., Hu Y., Zhang R., Ho M.S., Xue L. FoxO mediates APP-induced AICD-dependent cell death. Cell Death Dis. 2014, 5:e1233.
228. Weatherbee S.D., Anderson K.V., Niswander L.A. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 2006, 133:4993-5000.
229. Weeber E.J., Beffert U., Jones C., Christian J.M., Forster E., Sweatt J.D., Herz J. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J.Biol. Chem. 2002, 277:39944-39952.
230. Weggen S., Beher D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimers Res Ther 2012, 4:9.
231. Willnow T.E., Hilpert J., Armstrong S.A., Rohlmann A., Hammer R.E., Burns D.K., Herz J. Defective forebrain development in mice lacking gp330/megalin. Proc. Natl. Acad. Sci. USA 1996, 93:8460-8464.
232. Woo J.A., Jung A.R., Lakshmana M.K., Bedrossian A., Lim Y., Bu J.H., Park S.A., Koo E.H., Mook-Jung I., Kang D.E. Pivotal role of the RanBP9-cofilin pathway in Aβ-induced apoptosis and neurodegeneration. Cell Death Differ. 2012, 19:1413-1423.
233. Wu J., Petralia R.S., Kurushima H., Patel H., Jung M.Y., Volk L., Chowdhury S., Shepherd J.D., Dehoff M., Li Y., et al. Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation. Cell 2011, 147:615-628.
234. Xu N.J., Henkemeyer M. Ephrin reverse signaling in axon guidance and synaptogenesis. Semin. Cell Dev. Biol. 2012, 23:58-64.
235. Xu Q., Walker D., Bernardo A., Brodbeck J., Balestra M.E., Huang Y. Intron-3 retention/splicing controls neuronal expression of apolipoprotein E in the CNS. J.Neurosci. 2008, 28:1452-1459.
236. Yamamoto T., Davis C.G., Brown M.S., Schneider W.J., Casey M.L., Goldstein J.L., Russell D.W. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984, 39:27-38.
237. Yang L., Wang B., Long C., Wu G., Zheng H. Increased asynchronous release and aberrant calcium channel activation in amyloid precursor protein deficient neuromuscular synapses. Neuroscience 2007, 149:768-778.
238. Yumoto N., Kim N., Burden S.J. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 2012, 489:438-442.
239. Zerbinatti C.V., Wozniak D.F., Cirrito J., Cam J.A., Osaka H., Bales K.R., Zhuo M., Paul S.M., Holtzman D.M., Bu G. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. USA 2004, 101:1075-1080.
240. Zerbinatti C.V., Wahrle S.E., Kim H., Cam J.A., Bales K., Paul S.M., Holtzman D.M., Bu G. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J.Biol. Chem. 2006, 281:36180-36186.
241. Zhang B., Luo S., Wang Q., Suzuki T., Xiong W.C., Mei L. LRP4 serves as a coreceptor of agrin. Neuron 2008, 60:285-297.
242. Zhang H., Ma Q., Zhang Y.W., Xu H. Proteolytic processing of Alzheimer's β-amyloid precursor protein. J.Neurochem. 2012, 120(Suppl 1):9-21.
243. Zhao W., Dumanis S.B., Tamboli I.Y., Rodriguez G.A., Jo Ladu M., Moussa C.E., William Rebeck G. Human APOE genotype affects intraneuronal Aβ1-42 accumulation in a lentiviral gene transfer model. Hum. Mol. Genet. 2014, 23:1365-1375.
244. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 2011, 12:723-738.